MRD-guided shorter chemo for slow-growing lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a shorter course of bendamustine and rituximab (chemotherapy plus antibody treatment) can work just as well for slow-growing non-Hodgkin lymphoma. It uses a special blood test to monitor cancer levels and decide if treatment can be safely reduced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a slow-growing type of non-Hodgkin lymphoma: follicular (grades 1-3a), marginal zone, or lymphoplasmacytic lymphoma.
- You can be starting treatment for the first time, or be in relapse, as long as you haven't had bendamustine before (or started it in the last 14 days).
- You must be 18 or older and have a good performance status (able to do daily activities with little help).
- Your blood counts (neutrophils and hemoglobin) must be at certain levels unless low due to lymphoma in the bone marrow.
- Your liver and kidney function must be within acceptable limits.
- A special test (ClonoSEQ) must find a unique cancer marker in your tumor so doctors can track your response.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
This trial tests a combination of chemotherapy and targeted therapy as a first treatment for mantle cell lymphoma. It uses special scans (PET-CT) and blood tests (MRD) to guide treatment decisions and aims to improve outcomes while reducing side effects.
This trial compares two different lengths of chemotherapy (4 cycles vs. 6 cycles) combined with two targeted drugs, polatuzumab vedotin and rituximab, for people with newly diagnosed DLBCL who have a low-risk score. The goal is to see if a shorter treatment works just as well with fewer side effects.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.